Thrombolysis is the biological defense against stroke and heart attacks. The natural human system uses two proteins, plasminogen activators, called tPA and prourokinase (proUK). These proteins bind to the surface of the occlusive clot in a specific order and trigger a cascade of events ending in the dissolution of the clot and the restoration of blood flow.

In the 1980s and 1990s, thanks to the development of biotechnology, several thrombolytic drugs were developed and used individually, as monotherapies.
It is time for a new-generation solution.